Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen
Haemophilia · 2023
DOI: 10.1111/hae.14851 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2023. Verfasst von Amanda Okolo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Indiana Haemophilia and Thrombosis Center, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Introduction
Treatment adherence is critical to minimize bleeding episodes in persons with haemophilia. Suboptimal adherence increases risk of adverse medical outcomes and negatively impacts quality of life. Assessment of treatment adherence is therefore an integral component of intervention to mitigate the adverse impacts of haemophilia.
Aim
To develop and validate a multifactorial, patient (self or caregiver) report adherence measure for emicizumab treatment and report the first patient‐report data on adherence to specific components of emicizumab treatment (dosing, timing, injection, planning and bleeds).
Methods
An IRB approved multi‐site prospective study enrolled 83 participants with factor VIII deficiency being treated with emicizumab. Participants completed the 25‐item VERITAS NexGen (self‐report from 50 adults age 18+ years; caregiver‐report from 33 parents of children aged 6 months to 17 years) as well as a global adherence rating (GAR) scale. Providers of participants also completed a GAR scale.
Results
Most VERITAS‐NexGen subscales had good‐to‐excellent internal consistency reliability, test‐retest reliability, and validity. VERITASNexGen scores revealed globally strong patient‐reported adherence; however timing and bleed management were reported as greater challenges to adherence compared to dosing and injections. Adults struggled more with timing and planning of injections than caregivers.
Conclusion
The VERITASNexGen is the first validated multifactorial patient‐report measure of adherence designed specifically for emicizumab treatment. Results suggest excellent adherence, with only 4%–13% of participants reporting suboptimal adherence to different components of the treatment regimen. Used in conjunction with other adherence measures, VERITAS‐NexGen meets a crucial need for monitoring and understanding patient adherence to emicizumab in clinical and research settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Indiana Haemophilia and Thrombosis Center, Indianapolis, Indiana, USA.
- Cancer and Blood Diseases Institute, Department of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Amanda Okolo, Amy Shapiro, Lisa Littner
Zitieren
APA
Okolo, A., Shapiro, A., Janson, I., Okungade, J., Roberson, C., Nolte, M., Littner, L., & Kronenberger, W. (2023). Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen. Haemophilia. https://doi.org/10.1111/hae.14851
Vancouver
Okolo A, Shapiro A, Janson I, Okungade J, Roberson C, Nolte M, et al. Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen. Haemophilia. 2023. doi:10.1111/hae.14851
BibTeX
@article{Okolo2023,
author = {Okolo, Amanda and Shapiro, Amy and Janson, Isaac and Okungade, James and Roberson, Chris and Nolte, MacKenzie and Littner, Lisa and Kronenberger, William},
title = {Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen},
journal = {Haemophilia},
year = {2023},
doi = {10.1111/hae.14851}
}
EUVIMED